Review product approvals granted by different national Regulatory Authorities between 2000 and 2011 to establish how many were for neglected diseases
last phase of drug development
updated 31 Dec 2013
The study recently published in the Lancet Global Health on the R&D landscape for Neglected diseases reviewed product approvals granted by different national Regulatory Authorities between 2000 and 2011. The objective was to update the findings published in 2002 showing a deficit of products for neglected diseases.
The new study found 850 new drugs and vaccines approved for all diseases among which only 37 were developed for all neglected diseases.
To promote open access and help other researchers, source data compiled for this study are being made available here. This comprehensive list includes all of the products approved at several authorities between 2000 – 2011 (Table 1).
Another part of the study assessed the number of pre-registration clinical trials (phase 1-3) for neglected diseases as registered at the cut-off date of 31st December 2011.
A total of 383 active trials and 123 new products were being studied. The detailed information of these new products is also made available here (Table 2).
The data collection methodology is described in the article.
We would like to thank Claudette Some and Belen Pedrique for compiling these data.
Table 1. List of New Products Registered between 2000 and 2011
Table 2. List of New Products in development in Active Clinical Trials at December 2011
DISCLAIMER: The researchers have extracted and interpreted the data from publicly available sources of data with due care and diligence. The data is not endorsed or verified by the relevant authorities, nor are they responsible for errors or omissions.
News & resources
- 25 February 2014 – Opening up data to accelerate research for neglected diseases and global health, The Lancet Global Health Blog
- 24 October 2013 – The drug and vaccine landscape for neglected diseases (2000—11): A systematic assessment, The Lancet Global Health
Get our latest news, personal stories, research articles, and job opportunities.